Elsevier · Tollefsbol, T: Translational Epigenetics Series · Information for prospective Translational Epigenetics chapter authors

Information for prospective Translational Epigenetics chapter authors

Information for prospective Translational Epigenetics chapter authors
Author Guidelines
Translational Epigenetics series
Edited by Dr. Trygve Tollefsbol

Preparation of Manuscript

Manuscripts should be concise and consistent in style, spelling, and use of abbreviations. When your manuscript is complete, please submit via EMSS (http://editorial.elsevier.com) using the instructions provided separately.

Co-authors

Lead authors may opt to enlist co-authors in the work. Contributors should be listed in order of their contribution and as they will appear in the final work. Please clearly designate a senior author for your chapter.

Schedule

Your chapter should be submitted in EMSS by your due date in EMSS. Please do not be late. The schedule of the full work depends heavily on timely submissions from all authors.

Please contact the Dr. Tollefsbol directly if there is any problem meeting this deadline.

Manuscript Length

Your manuscript should be roughly 9,000-10,000 words in length, not including figure legends and references, and contain between 2 and 6 figures, images, or tables, where appropriate. Please limit references to a maximum of one hundred (100).

Formatting and Submission  

Your manuscript should:

  • Be created in a conventional document format (.rtf, .doc, .docx)
  • Please do not use complicated formatting for the chapter or attempt to replicate the style. All formatting will be amended to uniform house style by the typesetter.
  • Be submitted electronically using the EMSS system
  • Be double-spaced
  • Include page numbers
  • Figures must be submitted separately as individual, high resolution files (see section figure specifics in this document). The printed version will be black and white while the digital versions will be in color. Please take this in account in your choice of figures.
    • These figures should have “call outs” within the manuscript, to let us know where you would like them to be placed.
    • Example:

***Insert Figure 1***

  • The tables should be prepared within Word and inserted in a Tablessection at the very end of the manuscript. See below for details.
    • These tables should have “call outs” within the manuscript, to let us know where you would like them to be placed.
    • Example:

***Insert Table 1***
Title Page

The Title Page (p. 1) should contain:

  • the article title (please do not use abbreviations in title)
  • authors' names in the order they should appear in the final print, together with affiliations
  • Please indicate corresponding author and include their contact details
  • Please also indicate the senior author on the work
  • A running title of less than 45 characters

Abstract (also known as Summary)

For each chapter to be accepted, a concise and factual abstract (150-250 words) is required.

  • The abstract should provide a brief review of the chapter and mention the key concepts addressed.
  • It will be presented separately from the article, so it must be able to stand alone.
  • Non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself. Any references should be spelled out in the abstract.
  • Note that this abstract is used on ScienceDirect for search and discovery applications.

Key Words

Immediately after the Abstract, please provide 5-10 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, “and”, “of”). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible.

General Outline

The intended audience is “Advanced undergraduate students, graduate students, health care professionals, university researchers, pharmaceutical companies interested in drug development and biotechnology companies. This book could also serve as a core textbook for advanced university or professional school courses with a focus on genetic and/ or human diseases.” Each book chapter should contain and present a concept or problem of interest, and provide conceptual as well as practical solutions.

The bulk of your chapter should follow this general outline, so as to ensure consistency throughout the book:

  1. Title Page, as described above
  2. Abstract & key words
  3. Outline of your chapter
  4. Body of the text
    1. Introduction to your topic
    2. Each new concept within your chapter should have its own Concept Heading.
    3. Conclusion. This section is intended to place the topic of each chapter within the broader context of personalized epigenetics. You might use this section to speculate on future research directions/trends.
  5. References
    1. Please include any references you make in the style outlined below. Please limit to 100 references.
  6. Glossary
    1. Please define any terms that you may use throughout your chapter.
  7. List of Acronyms and Abbreviations
    1. Please list out and define any acronyms or abbreviations that you introduce in your chapter.
  8. Figure Legend
    1. Please include any figure descriptions in this section.
  9. Tables
    1. Please insert your tables into this section.

Reference List and Text Citations

References should be completed in numbered (Vancouver) style.

  • References are numbered in order of their mention in the text.
  • Text citations should be enclosed (5) and set on the text line.
  • If it is necessary to insert new references after the manuscript has been typeset, do not renumber all references. Simply insert as 1a, 2b, etc.
  • References should list the first six authors before “et al” is used.
  • Suggested reference format:

1. Carrasquillo JA, Chen CC. Molecular imaging of neuroendocrine tumors. Seminars in oncology.   2010;37(6):662-79.

2. Von Moll L, McEwan AJ, Shapiro B, Sisson JC, Gross MD, Lloyd R, et al. Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1987;28(6):979-88.

3.  Watanabe N, Shimizu M, Kageyama M, Kitagawa K, Hayasaka S, Seto H. 123I-MIBG SPECT of Merkel cell carcinoma. The British journal of radiology. 1998;71(848):886-7.

Figures

Clearly number figures and indicate orientation. Each figure should have a descriptive legend, which should be typed together and included after the acronym section, double-spaced. Please indicate in the text where each table or figure should fall using a “call out”. Resolution for all images must be 300 dpi for halftones and 1200 dpi for line drawings, at final size.

The following formats are preferred:

  • Adobe Illustrator EPS files
  • Adobe PhotoShop EPS files
  • Adobe PhotoShop TIFF files
  • JPEG files, but only if saved with least amount of compression.
  • Please DO NOT embed EPS or TIFF files in WORD or POWER POINT
  • Please DO NOT use PDFs as these are not editable
  • Please DO NOT embed graphs, figures, photos, or other artwork within the text manuscript. Captions for figures should be included at the end of the text file, however.

Tables

  • Tables should be numbered consecutively in order of appearance in the text.
  • Authors should submit complex tables (these include tables with over 3 columns or any non-standard tables) as camera-ready copy.
  • Footnotes to tables should be placed at the bottom of the table and linked to the body of the table with the corresponding lowercase italic superscript letters.
  • If references to the literature appear only in a table, they should not be included in the main reference list. The complete reference should be given as a letter footnote to the table.

Permissions

  • The author is responsible for obtaining permission from the copyright owner (this is usually the publisher) if the author plans to use figures, illustrations, charts, tables, or other material from previously published sources. If you have any questions about obtaining permission or need help with a particular item, please contact your Editorial Project Manager.
  • If an author uses material from their own published work, permission must still be obtained from the publisher.
  • The source of the data must always be credited in a footnote to a table or a figure legend.
  • Please note that no copyrighted work will be allowed without appropriate permission.
  • When asking for permissions, please remember to ask for permission “in this and any future editions of the above book in any form” as well as “nonexclusive world rights in all languages.”
    • This will save you from having to ask for permissions several years from now when we publish a second or third edition of the book.
  • Many publishers DO NOT charge permission fees. These publishers have agreed to not charge permission fees for: a) up to 3 figures (including tables) from a journal article or book chapters; b) up to 5 figures (including tables) from a whole book; and c) single text extracts of less than 400 words or series of text extracts totaling less than 800 words.
  • To find publishers that do not charge Elsevier authors permissions fees as described above, please go to: http://www.stm-assoc.org/permissions-guidelines/
  • If you have permissions questions, please contact permissionshelpdesk@elsevier.com.

Equations

  • Equations, if included, should be numbered, using Arabic numbers enclosed in parentheses, in sequence throughout the article.
  • In the text, they should be referred to as Eq. (1), Eqs. (3)-(5); if the word “Equation” begins a sentence, it should be written out in full.

Proofs

  • Proofs will be sent to the corresponding author.
  • To avoid delay in publication, only necessary changes should be made, and proofs should be returned promptly within the deadline given when the proofs are sent.
  • Authors may be charged for alterations that exceed 10% of the total cost of composition.

If you have any questions, please contact your Editorial Project Manager.